Investigation of Antihypertensive Properties of Chios Mastic via Monitoring microRNA-21 Expression Levels in the Plasma of Well-Controlled Hypertensive Patients.
Maria TsotaPanagiota GiardoglouEvangelia Mentsiou-NikolaouPanagiotis SymianakisIoanna Panagiota KalafatiAnastasia-Areti Kyriazopoulou-KorovesiLasthenis AngelidakisMaria PapaioannouChristina Konstantakinull Hyper-Mastic ConsortiumKimon StamatelopoulosGeorgios V DedoussisPublished in: Non-coding RNA (2024)
Hypertension is a chronic, multifactorial disease, leading to high cardiovascular morbidity and mortality globally. Despite the advantages of pharmaceutical treatments, natural products have gained scientific interest due to their emerging phytotherapeutic properties. Chios mastic is a natural Greek product, consisting of bioactive compounds which modify microRNAs' (small, expression-regulating molecules) expression. In this study, we investigated the antihypertensive properties of Chios mastic through the assessment of miR-21 levels. Herein, plasma samples of 57 individuals with hypertension, recruited for the purposes of the HYPER-MASTIC study, were analyzed. This was a clinical trial with Chios mastic supplements in which the patients were divided into groups receiving high and low mastic doses and placebo supplements, respectively. miR-21 was significantly upregulated in patients compared to normotensive individuals. Mean changes in miR-21 levels were statistically significant, after adjusting for sex and age, between the placebo and low-dose group and between the low- and high-dose group. Post-intervention miR-21 levels were positively associated with night-time systolic blood pressure, pulse pressure, and central systolic mean arterial pressure and negatively associated with night-time pulse wave velocity in the low-dose group. Our findings suggest a potential implication of miR-21 in the association of Chios mastic with night-time blood pressure measurements.
Keyphrases
- blood pressure
- hypertensive patients
- long non coding rna
- low dose
- cell proliferation
- poor prognosis
- high dose
- heart rate
- end stage renal disease
- long noncoding rna
- clinical trial
- ejection fraction
- newly diagnosed
- chronic kidney disease
- randomized controlled trial
- prognostic factors
- peritoneal dialysis
- heart failure
- blood glucose
- depressive symptoms
- risk assessment
- patient reported outcomes
- open label
- sleep quality
- phase ii
- study protocol
- metabolic syndrome
- placebo controlled
- single molecule
- patient reported